Aarti Pharmalabs Limited has informed the Exchange about Investor Presentation
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Pharmalabs reported FY26 standalone revenue of ₹17,976 Mn with EBITDA of ₹4,061 Mn (22.6% margin) and PAT of ₹1,762 Mn (9.8% margin). Q4 FY26 revenue grew 9.5% YoY to ₹5,797 Mn, though EBITDA margin contracted sharply to 23.1% from 31.2% in Q4 FY25. The company cited geopolitical tensions causing input and logistics cost increases that could not be fully passed to API/Intermediates customers. CDMO segment achieved its highest-ever quarterly revenue of ₹155 Cr in Q4. The company targets 15-18% revenue and EBITDA CAGR over the next 3-4 years, plans to enter peptides and oligonucleotides (TIDES) via R&D in FY27, and expects Xanthine capacity expansion to 9,000 MTPA by June 2026. Capex for FY26 was approximately ₹400 Cr with similar levels expected for FY27.
Margin compression from input cost pressures and foreign exchange losses weighed on FY26 profitability, with PAT declining 31.5% YoY. The multi-year 15-18% CAGR target and CDMO growth momentum suggest a recovery path, but near-term headwinds from cost inflation may continue until capacity expansions and new product initiatives (TIDES) materialize.